The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Postsynthetic Modification of ZIF-90 for Potential Targeted Codelivery of Two Anticancer Drugs
Abstract
Combination therapy has been regarded as a promising strategy for cancer treatment due to the enhanced anticancer efficacy achieved by blocking multiple drug resistance pathways. In this work, a drug carrier based on nanoscale ZIF-90 for the codelivery of two anticancer drugs has been synthesized by covalently attaching doxorubicin (DOX) to the surface of ZIF-90 via Schiff base reaction of amino group in DOX and aldehyde group of imidazole-2-carboxaldehyde (ICA) ligand and encapsulating 5-fluorouracil (5-FU) into the pores of the framework. The results of drug loading measurements show that the loading amount of drugs was estimated as high as 36.35 and 11-13.5 wt % for 5-FU and DOX, respectively. Moreover, we demonstrated that the carrier had the potential of cancer-targeted delivery of drugs for the collapse of framework under the pH environment around cancer cells and subsequently releasing drugs. Drug release at pH 5.5, imitating the environment of tumor, can reach over 95%, and the release time is less 16 h, meaning a more effective and faster release of drugs around tumoral cells than that in a normal environment. This is the first report for cancer-targeted codelivery of two different chemical drugs based on nanoscale metal-organic frameworks (NMOFs).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
He, C., Lu, K., Liu, D., & Lin, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4098862 · Cited by 885
Cited by
Metal–Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications
Sun, Y., Zheng, L., Yang, Y., Qian, X., Fu, T., Li, X., Yang, Z., Yan, H., Cui, C., & Tan, W. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00423-3 · Cited by 723
Metal-organic frameworks for stimuli-responsive drug delivery
Wang, Y., Yan, J., Wen, N., Xiong, H., Cai, S., He, Q., Hu, Y., Peng, D., Liu, Z., & Liu, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119619 · Cited by 665
Mito‐Bomb: Targeting Mitochondria for Cancer Therapy
Guo, X., Yang, N., Ji, W., Zhang, H., Dong, X., Zhou, Z., Li, L., Shen, H., Yao, S. Q., & Huang, W. (2021) · Advanced Materials · doi:10.1002/adma.202007778 · Cited by 421
Synthesis and modification of ZIF-8 and its application in drug delivery and tumor therapy
Wang, Q., Sun, Y., Li, S., Zhang, P., & Yao, Q. (2020) · RSC Advances · doi:10.1039/d0ra07950b · Cited by 399
Metal-Organic Framework (MOF)-Based Drug Delivery
Cao, J., Li, X., & Tian, H. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666190618152518 · Cited by 282
Metadata
- Authors
- Zhang, F.-M., Dong, H., Zhang, X., Sun, X.-J., Liu, M., Yang, D.-D., Liu, X., & Wei, J.-Z.
- Venue
- ACS Applied Materials & Interfaces
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-08-04
- Volume
- 9
- Issue
- 32
- Pages
- 27332-27337
- ISSN
- 1944-8244 (ISSN-L)
- 1944-8252
- OpenAlex
- W2737608110
- Cited by
- 219
- References
- 2
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Postsynthetic Modification of ZIF-90 for Potential Targeted Codelivery of Two Anticancer Drugs. https://app.cochat.ai/papers/10.1021/acsami.7b08451
- The paper
- Zhang, F.-M., Dong, H., Zhang, X., Sun, X.-J., Liu, M., Yang, D.-D., Liu, X., & Wei, J.-Z. (2017). Postsynthetic Modification of ZIF-90 for Potential Targeted Codelivery of Two Anticancer Drugs. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.7b08451
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.